Atai Beckley’s $3.8 Billion Eli Lilly Takeover: The Stock Has Soared, But Analysts Are Hitting the Brakes

Atai Beckley stock hits multi-year highs on Eli Lilly's $3.8B acquisition offer, but analysts downgrade shares as focus shifts from pipeline to deal closure risks.

Eli Lilly’s decision to acquire Atai Beckley for up to $3.8 billion has sent the stock rocketing to multi-year highs, yet a growing chorus of analysts is downgrading the shares even as they trade near the offer price. The disconnect highlights a fundamental shift in the investment thesis: the stock is no longer a bet on clinical trial data, but a play on whether the deal actually closes.

The cash component of the transaction stands at $6.75 per share, valuing Atai Beckley’s equity at roughly $2.8 billion. On top of that, shareholders will receive contingent value rights (CVRs) worth up to an additional $2.50 per share, tied to future development and regulatory milestones for the company’s lead programs, BPL-003 and VLS-01. If all milestones are met, the total deal value could reach $3.8 billion.

The market, however, is pricing the CVRs well below their theoretical maximum. That caution is understandable: the CVRs are not publicly traded and are difficult to transfer, meaning investors who hold them will bear the full clinical and regulatory risk for four to seven years — with the very real possibility of receiving nothing at the end.

A Rally That Hasn’t Convinced Everyone

Atai Beckley shares closed at €6.20 on Tuesday, marking a 32.48% gain over the past week and a staggering 75.14% increase over the past month. The stock has climbed 76.55% over the last 30 days, currently sitting at €6.25. Yet the relative strength index (RSI) has hit 74.3, signaling overbought conditions, while the annualized 30-day volatility of roughly 121% underscores the wild swings surrounding the offer.

Despite the rally, analysts at H.C. Wainwright and Berenberg have lowered their ratings, and several other firms have either slashed or withdrawn their price targets entirely. The reasoning is consistent: the agreed takeover price caps the stock’s upside. The investment story has pivoted from pipeline progress to deal probability.

The Regulatory and Shareholder Hurdles

Securing shareholder approval is far from a foregone conclusion. Apeiron and Angermayer, two major investors, have signed voting agreements committing their combined 56.8 million shares — representing 15.4% of voting rights as of June 22, 2026 — to support the deal. But that is well short of the majority needed. The stock’s current price already reflects the risk that the vote could fail.

On top of that, antitrust clearance is required. The deal has an initial six-month closing period, which can be extended to nine months if regulators drag their feet. Both hurdles are now the primary drivers of the stock, replacing any focus on clinical milestones.

A Broader Biopharma M&A Wave

The Atai Beckley acquisition is part of a broader push by Eli Lilly into neuroscience and central nervous system therapies. Just days after announcing the Atai deal, the company revealed plans to acquire Centessa Pharmaceuticals for roughly $6.3 billion, plus up to $1.5 billion in milestone payments. Centessa’s candidate, cleminorexton, is in a Phase 2a study for narcolepsy and idiopathic hypersomnia.

The Atai deal also signals Big Pharma’s growing seriousness about psychedelic treatments for mental health. The global psychedelic drug market is projected to reach $8.75 billion by 2031, according to Mordor Intelligence, with tailwinds from a Trump administration directive to accelerate FDA reviews of psychedelic compounds. Other players are benefiting too: Definium Therapeutics saw its stock jump roughly 50% on positive results for its LSD-based depression drug DT120, while Jupiter Neurosciences secured exclusive U.S. rights to PharmAla’s MDMA candidate ALA-002 in a deal worth up to $100 million.

What Comes Next

With the takeover premium largely baked into the share price, Atai Beckley’s near-term trajectory hinges on three events: the release of the definitive proxy statement, the shareholder meeting date, and progress on antitrust review. Clinical data for BPL-003, once the centerpiece of the story, has taken a back seat.

For Eli Lilly, the Atai Beckley purchase fits into an exceptionally active M&A year. The second quarter of 2026 saw roughly $80 billion in biopharma mergers and acquisitions, along with $83 billion in licensing and research partnerships, according to Endpoints News — a clear recovery for the sector. Whether Atai Beckley shareholders ultimately collect the full $3.8 billion, or only the cash portion, will depend on how the next few months unfold.